Board summary
Key figures
36,731
Registered population
54.4% aged 18–64
29.6%
Aged 65+
ICB 21.9% · England 17.9%
4.5%
Ethnic minority (non-White)
1.8% Asian · England 9.6%
9.4%
In IMD quintile 1
ICB 9.2% · England 21.0%
~3,081
Core20 residents (est.)
Resident basis; registered basis ~3,278 · see page 3
7,368
Hypertension register
+3.54% in 3 yrs · England +5.60%
478
SMI register
23.9% of Arun's
1,053
COPD register
Reviews -3.92% in 3 yrs
Forecast to 2030
8,286
Hypertension patients, 2030
+918 on today
71.2%
QRISK ≥20% on statins, 2030
+5.69pp over 3 yrs
6.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews lag and declined.
Asthma reviews are 59.8% (England 65.7%) after a -6.9% three-year change (England +4.4%), leaving 1,174 patients unreviewed; this may reflect recall gaps, unverified locally.
High-risk lipid therapy lags despite higher unit costs.
Lipid therapy is 57.9% for QRISK ≥ 20% (England 63.6%) and 61.7% for CKD (England 70.3%), while items cost £3.20 (England £1.86).
Hypertension blood pressure control exceeds benchmarks.
Hypertension prevalence is 19.9% (England 15.2%), yet blood pressure control reaches 72.7%, above Arun (68.8%), the ICB (69.1%) and England (70.3%).
Population, age and ethnicity
Patients aged 65+ comprise 29.6% of the list, well above England
Across 36,731 registered patients, 29.6% (10,885 patients) are aged 65+, above Arun (29.2%), NHS Sussex Integrated Care Board (21.9%), and England (17.9%). Working-age adults (18-64) make up 54.4% (19,981 patients), below Arun (54.9%), the ICB (60.5%), and England (62.7%), while aged 0-17 comprise 16.0% (5,865 patients). Registered list size is projected to grow 3.3% by 2030 (Arun 2.7%; ICB 2.1%; England 2.3%; unverified methodology). Census resident data show 95.5% White ethnicity (Arun 95.8%; ICB 91.0%; England 81.1%), with 4.5% ethnic minorities; these describe local residents rather than registered patients.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Arun local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Arun LA) | 2,327 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 80.4% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.8% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Arun LA) | 1,216 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Arun LA) | 13.3 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 9.4% overall but reaches 16.1% at Maywood Health Care Centre
The PCN Core20 share is 9.4%, below England (21.0%) and Arun (9.8%) but in line with NHS Sussex Integrated Care Board (9.2%), with an average IMD decile of 5.5. Weighted practice share is 8.9%, reflecting different source bases. Deprivation concentrates in Maywood Health Care Centre with a 16.1% share (an estimated 2,849 patients), while West Meads Surgery has 5.5% (429 patients) and Grove House Surgery has 0.0%. Associated LSOAs contain an estimated 3,081 residents across deciles 1 and 2. Observation periods are unconfirmed.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
478
SMI register
1.29% recorded prevalence
362
Learning disability register
0.98% recorded prevalence
38
Care homes, 941 beds
In the PCN catchment
8.9%
Provide unpaid care
Arun, Census 2021
The PCN records 362 learning disability patients (1.0%; Arun 0.8%, NHS Sussex Integrated Care Board 0.6%, England 0.6%) and 478 severe mental illness patients (1.3%; Arun 1.1%, NHS Sussex Integrated Care Board 1.1%, England 1.0%). The catchment contains 38 care homes (941 beds). Modelled ceiling estimates indicate about 3,300 unpaid carers, though practice counts were not captured.
Severe mental illness: physical health checks
SMI prevalence is 1.3% (478 patients). Recorded blood pressure checks reach 79.9% (England 83.4%) and BMI recording reaches 81.6% (England 82.1%). Cardiovascular monitoring for SMI patients lags national rates, indicating an opportunity to tighten annual physical health recall.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,368
Hypertension register
+3.54%
Register growth, 3 yrs
Arun +4.55% · England +5.60%
+3.27pp
BP control, under 80
≤140/90 · +0.01pp aged 80+
+918
More patients by 2030
Forecast 8,286 (21.37%)
Hypertension case-finding and control
Hypertension prevalence is 19.9% (7,368 patients), above England (15.2%), Arun (19.8%) and NHS Sussex Integrated Care Board (16.3%), which is consistent with an older population where 29.6% are aged 65+. Blood pressure treated to target is 72.7%, exceeding England (70.3%), Arun (68.8%) and the ICB (69.1%). For patients aged under 80, control reaches 69.7% (England 67.8%), though Maywood Health Care Centre records 66.2%. Recent blood pressure readings reached 89.2% (England 90.0%), with three-year growth of +1.4% trailing England (+3.6%). Crude register prevalence does not establish undiagnosed disease. Strong overall blood pressure control alongside trailing monitoring growth suggests systematic recall could sustain management across the expanding older cohort.
Lipids and statins
Lipid-lowering therapy lags England across high-risk groups: QRISK ≥ 20% is 57.9% (England 63.6%), CKD is 61.7% (England 70.3%), and diabetes without CVD is 68.7% (England 73.2%). Fewer at-risk patients receive lipid-lowering therapy than national rates imply, so a targeted recall of eligible primary prevention cohorts is the key opportunity.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 69,004 | £3.20 | £2.42 | £1.86 | £220,813 |
| Cardiovascular (all), 2025 | 91,552 | £4.25 | £3.32 | £3.33 | £389,096 |
For lipid-modifying drugs in 2026, the PCN prescribed 69,004 items at £3.20 per item, spending £92,465 more than at England's unit cost (£1.86; NHS Sussex Integrated Care Board £2.42). Unit cost does not reflect clinical appropriateness. Spending more per item than comparators while treatment rates trail national levels highlights an opportunity to review formulary choices and statin initiation.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−6.88%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.22%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 8.2% (2,919 patients; England 6.6%) and COPD is 2.9% (1,053 patients; England 1.9%). Over 2023 to 2025, annual reviews fell -6.9% for asthma to 59.8% (England +4.4%; 65.7%), leaving an estimated 1,174 patients unreviewed, and -3.9% for COPD to 70.5% (England +2.8%; 76.4%). Youth asthma prescribing is 2,059 per 1,000 (England 1,488) and second-hand smoking recording is 70.8% (England 78.8%). Falling review rates alongside high youth prescribing may reflect recall gaps, unverified locally.
Cancer register and children's immunisation
Cancer register prevalence is 5.7% (2,118 patients; England 3.8%). In Q1 2025/26, age-5 coverage reaches 96.2% for MMR dose 1, but drops 6.3 pp to 89.9% for MMR dose 2 (England 82.8%), sitting below the 95.0% target by 5.1 pp. Pre-school 4-in-1 booster coverage also matches 89.9% (England 80.9%). Second-dose drop may reflect recall gaps, which clinical audit would test.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In 2022, 58.5% of staged cancers (4,799 of 8,209 with known stage) across NHS Sussex ICB were diagnosed at stage 1 or 2, above England (55.3%) but below the 75.0% national ambition by 16.5 pp, an ICB gap of about 1,360 early-stage cases. Known stage was recorded for 64.3% of registered cancers (8,209 of 12,766). These ICB figures describe the wider system, not PCN performance. At PCN level, recorded cancer prevalence is 5.7% (2,118 patients). Cervical screening coverage is 69.5% (England 66.8%) but fell 2.4% over three years (England -1.0%), while breast screening coverage fell 2.0% to 69.3% (England +8.4%).
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the cancer 62-day standard, trailing University Hospital Southampton NHS Foundation Trust (74.4%), Portsmouth Hospitals University NHS Trust (75.2%), NHS Surrey and Sussex Integrated Care Board (71.5%), and England (71.2%), falling below the 85.0% standard by 19.8 pp. The 28-day faster diagnosis standard reached 74.0% (England 79.3%). For all diagnostic tests, 12.9% waited 6+ weeks (England 23.1%), though colonoscopy waits reached 39.3% (England 30.8%). These provider and ICB waiting times describe the wider system, not PCN performance.
| Pathways within standard (%) | Sussex | Portsmouth | Southampton | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 66.81 | 75.07 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 94.78 | 86.76 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 75.20 | 74.44 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | Portsmouth | Southampton | England |
|---|---|---|---|---|
| MRI | 5.62 | 50.36 | 14.30 | 21.40 |
| CT | 8.57 | 13.06 | 16.47 | 9.92 |
| Echocardiography | 0.39 | 32.75 | 14.58 | 28.48 |
| Colonoscopy | 39.35 | 82.52 | 15.84 | 30.83 |
| Gastroscopy | 20.02 | 74.88 | 18.47 | 29.02 |
| All 15 DM01 tests | 12.95 | 51.96 | 20.84 | 23.14 |
| Community services activity | West Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 78,050 | 309,615 |
| Referrals | 16,015 | 66,930 |
| Patients with a contact | 19,770 | 85,660 |
Community services (residents of West Sussex), Jun 2026 (provisional). In June 2026, West Sussex recorded 78,050 community care contacts across 19,770 patients, with adults aged 65+ accounting for 72.7% of contacts (56,740). NHS Surrey and Sussex Integrated Care Board recorded 309,615 contacts across 85,660 patients. These provisional figures describe local authority and system activity rather than PCN performance, though 29.6% of the PCN's registered list is aged 65+.
Practice variation and patient experience
Overall QOF reaches at least 97.2% across practices, while vaccination varies by 14.7 pp
In 2025/26, overall QOF achievement exceeded England's 92.5% across all three practices: Grove House Surgery reached 99.3%, Maywood Health Care Centre reached 97.9%, and West Meads Surgery reached 97.2%. In contrast, vaccination and immunisation domain achievement spanned 14.7 pp: Grove House Surgery achieved 94.2%, Maywood Health Care Centre achieved 81.8%, and West Meads Surgery achieved 79.5%.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Maywood Health | 96 | 16.1 | 71.0% | 54.5% | 86.2% |
| West Meads Surgery | 104 | 5.5 | 71.2% | 79.3% | 80.2% |
| Grove House | 104 | 0.0 | 59.3% | 71.8% | 76.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Sixteen of 25 tracked measures trail England over three years, led by reviews
Across 25 tracked measures, 16 trailed England's three-year change. Annual asthma reviews fell 6.9% (England +4.4%), breast screening fell 2.0% (England +8.4%), COPD reviews fell 3.9% (England +2.8%), and heart failure reviews rose +2.2% (England +8.7%). Severe mental illness blood pressure checks rose +2.0 pp, trailing England (+4.4 pp) to reach 79.9% (England 83.4%). Conversely, high-risk lipid therapy rose +10.9% (England +6.2%), psychosis alcohol recording rose +8.2 pp (England +5.4 pp), and learning disability prevalence expanded +11.6% to 1.0% (362 patients; England +5.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
Breast screening (53-70)
COPD reviews
Heart failure reviews
Dementia register
QRISK statin treatment
Alcohol record (psychosis)
Smoking support (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Arun | Asset | PCN | Arun |
|---|---|---|---|---|---|
| Care homes (catchment) | 38 (941 beds) | n/a | Schools (catchment) | 18 | n/a |
| Children's centres | 2 | 7 | Places of worship | 15 | 68 |
| Libraries | 2 | 7 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 7 | 21 | Primary academies | 7 | 19 |
| Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured respiratory recall and inhaler review
Asthma reviews fell 6.9% over 2023 to 2025 to 59.8% (England 65.7%, +4.4%), leaving 1,174 of 2,919 patients unreviewed; COPD reviews fell 3.9% to 70.5% (England 76.4%, +2.8%). For discussion: run a single-template respiratory recall with after-school slots for children, combining inhaler prescribing and smoking checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
High-risk lipid initiation and formulary review
Lipid therapy lags England for QRISK ≥ 20% at 57.9% (England 63.6%), CKD at 61.7% (70.3%), and diabetes at 68.7% (73.2%); 69,004 items at £3.20 cost £92,465 more than England's £1.86 unit cost. For discussion: pair hypertension reviews with a pharmacist search for untreated high-risk cohorts alongside a formulary review. Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Option 3
Pre-school MMR and booster recall
In Q1 2025/26, age-5 MMR dose 2 and 4-in-1 booster coverage are both 89.9% (cohort 79; England 82.8% and 80.9%), below the 95.0% target by 5.1 pp and down 6.3 pp from dose 1 (96.2%). Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older population care coordination (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension monitoring recall audit (p5) | Hypertension patients with a recent blood pressure reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall outreach (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Screening recall protocol review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | — | PCN |
| Online access review (p9) | GPPS easy to contact the practice using its website | 10YHP, hospital to community | Practice |
| Option 1 · Structured respiratory recall and inhaler review (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · High-risk lipid initiation and formulary review (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · CKD patients treated with lipid lowering therapy · Patients with diabetes (40+ yrs no history of CVD) treated with a statin (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Pre-school MMR and booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target · Core20PLUS5 · 10YHP equity test | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
